Direct oral anticoagulants in obese patients with venous thromboembolism: results of an expert consensus panel
RP Rosovsky, E Kline-Rogers, L Lake… - The American journal of …, 2023 - Elsevier
In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous
thromboembolism are also obese. International guidance published in 2016 stated that
DOACs could be used in standard doses in patients with obesity up to a body mass index
(BMI) of 40 kg/m 2, but should not be used in those with severe obesity (BMI> 40 kg/m 2)
owing to limited supporting data at the time. Although updated guidance in 2021 removed …
thromboembolism treatment and prevention. A substantial proportion of patients with venous
thromboembolism are also obese. International guidance published in 2016 stated that
DOACs could be used in standard doses in patients with obesity up to a body mass index
(BMI) of 40 kg/m 2, but should not be used in those with severe obesity (BMI> 40 kg/m 2)
owing to limited supporting data at the time. Although updated guidance in 2021 removed …
以上显示的是最相近的搜索结果。 查看全部搜索结果